- Martínez García de la Torre, Raquel A.
- Vallverdú, Julia
- Xu, Zhenqing
- Ariño, Silvia
- Ferrer-Lorente, Raquel
- Zanatto, Laura
- Mercado-Gómez, Maria
- Aguilar-Bravo, Beatriz
- Ruiz-Blázquez, Paloma
- Fernandez-Fernandez, Maria
- Navarro-Gascon, Artur
- Blasco-Roset, Albert
- Sànchez-Fernàndez-de-Landa, Paula
- Pera, Joan
- Romero-Moya, Damia
- Ayuso Garcia, Paula
- Martínez Sánchez, Celia
- Sererols Viñas, Laura
- Cantallops Vilà, Paula
- Cárcamo Giráldez, Carmen I.
- McQuillin, Andrew
- Morgan, Marsha Y.
- Moya-Rull, Daniel
- Montserrat, Núria
- Eberlé, Delphine
- Staels, Bart
- Antoine, Bénédicte
- Azkargorta, Mikel
- Lozano, Juan-José
- Martínez-Chantar, Maria L.
- Giorgetti, Alessandra
- Elortza, Félix
- Planavila, Anna
- Varela-Rey, Marta
- Woodhoo, Ashwin
- Zorzano, Antonio
- Graupera, Isabel
- Moles, Anna
- Coll, Mar
- Affo, Silvia
- Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs' commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease., P.S-B. is supported by Instituto de Salud Carlos III (ISCIII) “PI20/00765”, PI23/00724, “FORT23/00002”, “DTS22/00032”, AGAUR, “2021 PROD 00035”, 23-0356; Dissecting the role of the 14q32 region in hepatoblastoma “Hblast14” Worldwide Cancer Research; PRYCO223102ARME; Scientific Foundation of the Spanish Association Against Cancer (AECC); Q6922, (B-ORG) Plan Complementario de Biotecnología aplicada a la Salud del Plan de Recuperación, Transformación y Resiliencia. Ministerio de Ciencia e Innovación and co-founded the European research and innovation program Horizon HORIZON-HLTH−2022-STAYHLTH-02 under agreement no. 101095679. R.A M-G is funded by Instituto de Salud Carlos III “FI18/00215”, S.A. received a grant from the Ministerio de Educación, Cultura y Deporte “FPU17/04992”, C.M is funded by Centro de Investigación en Red Enfermedades Hepáticas y Digestivas (CIBERehd). A.G. is supported by Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/ Generalitat de Catalunya for institutional support. J.P. is supported by La Marató de TV3 (202001-32). D.R-M. is supported by Deutsche José Carreras Leukämie-Stiftung (DJCLS 13 R/2022). A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC 2016-19731; by Pfizer grant #77131383; P.R.B. was funded by Ministerio de Universidades fellowships FPU19/05357; M.F.F. was funded by FPU20/01367. M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/ AEI/10.13039/501100011033), Proyecto LABAECC2024 (funded by Asociación Española Contra el Cáncer, AECC), HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). This study was funded by Instituto de Salud Carlos III through the Biobanks and Biomodels Platform and co‐funded by the European Union (PTC20/00013, PT20/00130, PT23/00009 and PTC23/00002 to N.M.) and by Instituto de Salud Carlos III and European Union—Next Generation EU, Plan de Recuperación Transformación y Resiliencia (TERAV/ISCIII RD21/0017/0018) to N.M; M.C. was funded by Ramon y Cajal programme from the Ministerio de Ciencia e Innovación RYC2019-026662-I. S.A. is funded by la Caixa Foundation “100010434” and the European Union’s Horizon 2020 under the Marie Skłodowska-Curie “847648”, PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312*. Ramon y Cajal program RYC2022-036321-I. (* Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them”)., Peer reviewed